WordNet

a period in a mans life corresponding to menopause

PrepTutorEJDIC

肉体の転換期;厄(やく)年 / 更年期

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/01/30 12:34:35」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 閉経の臨床症状および診断 clinical manifestations and diagnosis of menopause
2. ホルモン療法を用いた閉経期症状の治療 treatment of menopausal symptoms with hormone therapy
3. 更年期のほてり menopausal hot flashes
4. 健常女性における卵巣の発達および機能不全（閉経） ovarian development and failure menopause in normal women
5. 原発性早期卵巣障害（早期卵巣機能不全）の病因と原因 pathogenesis and causes of spontaneous primary ovarian insufficiency premature ovarian failure

English Journal

Role of bisphosphonates in postmenopausal women with breast cancer.

Gnant M.Author information Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.AbstractData suggest that bisphosphonates protect bone health and may have anticancer activity in postmenopausal women during adjuvant breast cancer therapy. However, key questions remain surrounding the role of adjuvant bisphosphonates in breast cancer, including patient populations deriving benefit, timing/scheduling of therapy, and specific clinical benefits. PubMed, Embase, and San Antonio Breast Cancer Symposium databases provide study results that address these issues in postmenopausal women. Review of these data would aid physicians in providing optimal management of breast cancer in postmenopausal women. For example, recent data reinforce use of intravenous bisphosphonates concurrently with adjuvant endocrine therapy to ameliorate bone loss in recently postmenopausal or osteopenic postmenopausal women with early breast cancer. In contrast, clinical data for oral bisphosphonates have not provided support for using anti-osteoporosis doses in this setting, and the optimal dose is unclear. Additionally, current clinical data show improvements in disease outcomes with bisphosphonates in many studies, although not in all patient subsets. Strong support for the potential adjuvant anticancer benefits from bisphosphonates has been demonstrated in women with established menopause (i.e., very low circulating estrogen levels). Initiating bisphosphonates early and concomitantly with adjuvant therapy generally provided the greatest benefits. However, questions remain such as schedule of treatment and relative potency among the intravenous bisphosphonates and elucidation of the role of oral bisphosphonates, as well as ongoing studies that might provide clarification. This review addresses these controversies in the context of translational research, which may provide the rationale for ongoing studies and evolving treatment paradigms in this area.
Cancer treatment reviews.Cancer Treat Rev.2014 Apr;40(3):476-84. doi: 10.1016/j.ctrv.2013.07.003. Epub 2013 Jul 29.
Data suggest that bisphosphonates protect bone health and may have anticancer activity in postmenopausal women during adjuvant breast cancer therapy. However, key questions remain surrounding the role of adjuvant bisphosphonates in breast cancer, including patient populations deriving benefit, timin
PMID 23906846

Chinese Men's Knowledge and Risk Factors of Osteoporosis: Compared With Women's.

Wong CP, Lok MK, Wun YT, Pang SM.Author information 1Health Bureau, Macau Special Administrative Region, Macau, China.AbstractMale osteoporosis is underappreciated. Little is known about men's knowledge of osteoporosis and how much men are at risk. This study surveyed men's knowledge of osteoporosis and their risk factors with reference to women in the primary care setting in Macau, China. A convenience sample of 302 men and 635 women aged 18 to 90 years completed questionnaires comprising the Osteoporosis Knowledge Assessment Tool and the One-Minute Osteoporosis Risk Test. Their risks of osteoporosis were assessed with the Osteoporosis Self-Assessment Screening Test. Men and women, who were aged 55 years or below, had similarly limited knowledge of osteoporosis. People aged above 55 years had significantly less knowledge; men had less knowledge than women only in this age-group. If questions specific to women or menopause were excluded, men had similar knowledge as women. A higher proportion of men than women had risk factors as more men consumed alcohol or smoked tobacco. Similar proportions of men and women reported a loss of 1 inch in body height after age 40. After age 55, 29.2% men were at medium to high risk of osteoporosis. This study concludes that health education and primary prevention of osteoporosis should be promoted to men starting in middle-age.
American journal of men's health.Am J Mens Health.2014 Mar;8(2):159-66. doi: 10.1177/1557988313503981. Epub 2013 Sep 11.
Male osteoporosis is underappreciated. Little is known about men's knowledge of osteoporosis and how much men are at risk. This study surveyed men's knowledge of osteoporosis and their risk factors with reference to women in the primary care setting in Macau, China. A convenience sample of 302 men a
PMID 24027205

A5.10 Therapeutic education of patients treated for osteoarthritis: Medical advice and assessment of patients knowledge level.

Nassar K, Janani S, Rachidi W, Mkinsi O.Author information Department of Rheumatology, University Hospital, Casablanca.AbstractINTRODUCTION: Osteoarthritis is the most common and debilitating degenerative arthropathy. Prevention and patient education are part of the international recommendations. A survey was realised between January and July 2012 with 43 medical specialists at the Hospital University of Casablanca, about their point of views on the role of therapeutic education for patients with osteoarthritis of the lower limb. Doctors justified the importance of patient education.
Annals of the rheumatic diseases.Ann Rheum Dis.2014 Mar 1;73 Suppl 1:A67. doi: 10.1136/annrheumdis-2013-205124.152.
INTRODUCTION: Osteoarthritis is the most common and debilitating degenerative arthropathy. Prevention and patient education are part of the international recommendations. A survey was realised between January and July 2012 with 43 medical specialists at the Hospital University of Casablanca, about t
PMID 24489279